Martynowicz Jennifer, Gutch Sarah, Capitano Maegan
Department of Psychiatry.
Department of Microbiology and Immunology, Indiana University School of Medicine; Indianapolis, Indiana, USA.
Curr Opin Hematol. 2025 Jul 1;32(4):187-192. doi: 10.1097/MOH.0000000000000874. Epub 2025 Apr 25.
The incidence of mental health conditions within hematopoietic stem cell transplant (HSCT) patients is high and has profound impacts on quality of life after transplant. Mental health is an underexplored and underutilized outcome in this patient population.
Standard mental health interventions in this patient population have shown limited results. Multiple factors including acuity of systemic illness, proinflammatory states, heterogeneous patient populations, and use of specific therapeutics could impact results. This presents the opportunity to identify new areas of improvement, such as focusing on leukocyte recovery, exogenous steroid use, and cytokine response to inform new bedside interventions.
Overall, interventions incorporating the biological mechanisms of mental health are underutilized in the HSCT patient population and offer a novel approach to improving morbidity, mortality and quality of life.
造血干细胞移植(HSCT)患者中精神健康状况的发生率很高,且对移植后的生活质量有深远影响。在这一患者群体中,精神健康是一个未被充分探索和利用的结果。
针对这一患者群体的标准精神健康干预措施效果有限。包括全身疾病的严重程度、促炎状态、异质性患者群体以及特定治疗方法的使用等多种因素可能会影响结果。这为确定新的改进领域提供了机会,例如关注白细胞恢复、外源性类固醇的使用以及细胞因子反应,以为新的床边干预提供依据。
总体而言,结合精神健康生物学机制的干预措施在HSCT患者群体中未得到充分利用,为改善发病率、死亡率和生活质量提供了一种新方法。